Advanced Stem Cell Procedure at Chughtai Lab

Stem Cell Procedure at Chughtai Lab

The Stem Cell Procedure (In Case Of Additional Charged) at Chughtai Lab represents a highly specialized, state-of-the-art cellular processing and diagnostic service designed to support regenerative medicine, advanced hematology, and oncology therapies. Stem cells are the body’s raw materials—cells from which all other cells with specialized functions are generated. In clinical practice, the harvesting, isolation, characterization, and preparation of these cells require an ultra-sterile environment, sophisticated laboratory equipment, and highly trained cellular pathologists. Chughtai Lab, a premier diagnostic institution in Pakistan, provides this advanced processing service to ensure that cellular products meet the stringent quality and safety standards required for therapeutic transplantation or regenerative treatments.

The clinical term “In Case Of Additional Charged” refers to the supplementary laboratory protocols, specialized reagents, extended processing times, or advanced cell-sorting technologies (such as CD34+ immunomagnetic selection) that may be required based on the specific clinical needs of the patient. Because stem cell processing is highly individualized, the baseline procedure may require additional specialized steps to ensure cell viability, purity, and safety. This procedure primarily evaluates and processes hematopoietic stem cells (HSCs) or mesenchymal stem cells (MSCs) derived from bone marrow, peripheral blood, or umbilical cord blood. By utilizing advanced flow cytometry, automated cell counters, and sterile cleanroom environments, Chughtai Lab delivers a highly reliable cellular product that clinicians can confidently utilize for therapeutic interventions.

The diagnostic and clinical value of this procedure is immense. It ensures that the stem cells harvested from a donor or the patient themselves (autologous) are viable, free from microbial contamination, and present in sufficient quantities to achieve therapeutic efficacy. Without rigorous laboratory processing and characterization, stem cell therapies carry significant risks of graft failure, contamination, or sub-therapeutic outcomes. Chughtai Lab’s dedicated molecular and cellular pathology divisions provide the critical quality control link between cell harvesting and clinical administration, helping patients undergoing treatment for hematological malignancies, bone marrow failure, and complex degenerative conditions.

Clinical Procedure: What to Expect

Patient Preparation

Patient preparation for a stem cell procedure depends significantly on whether the patient is undergoing autologous harvesting (using their own cells) or receiving processed cells. Because Chughtai Lab performs the critical laboratory processing phase, patients must follow specific clinical guidelines provided by their referring hematologist or oncologist prior to the collection of the biological sample. The following preparation guidelines are standard for patients undergoing stem cell harvesting:

• Medication Review: Patients must inform their physician of all medications, supplements, and herbal remedies they are taking. Anticoagulants, antiplatelet agents, and non-steroidal anti-inflammatory drugs (NSAIDs) may need to be temporarily discontinued to minimize bleeding risks during bone marrow aspiration or apheresis.
• Mobilization Therapy: For peripheral blood stem cell harvesting, patients typically receive daily injections of granulocyte colony-stimulating factor (G-CSF) for several days prior to collection. This medication mobilizes stem cells from the bone marrow into the bloodstream, maximizing the yield during apheresis.
• Hydration and Nutrition: Excellent hydration is critical in the days leading up to peripheral blood stem cell collection. Patients are advised to drink plenty of fluids and consume a balanced diet rich in calcium, as apheresis can temporarily lower blood calcium levels.
• Fasting Requirements: If the stem cell harvesting involves bone marrow aspiration under conscious sedation or general anesthesia, a fasting period of 8 to 12 hours prior to the procedure is strictly required.
• Pre-Procedure Screening: Comprehensive infectious disease screening (including Hepatitis B, Hepatitis C, HIV, and Syphilis) and a complete blood count (CBC) must be completed and verified before processing can begin at Chughtai Lab.

During the Procedure

The stem cell procedure encompasses two distinct phases: the clinical harvesting of the biological sample and the subsequent advanced laboratory processing at Chughtai Lab. During the harvesting phase, which takes place in a specialized clinical or hospital setting, the patient is positioned comfortably. For bone marrow harvesting, the patient lies prone, and a specialized needle is inserted into the posterior iliac crest (hip bone) under local anesthesia or sedation to aspirate the marrow. For peripheral blood harvesting, the patient is connected to an apheresis machine via intravenous lines, and stem cells are filtered out of the blood over a period of three to four hours.

Once the sample is collected, it is immediately transported to Chughtai Lab’s specialized cellular processing facility under strict temperature-controlled conditions. In the laboratory, scientists work within a certified sterile laminar flow hood (cleanroom environment). The sample undergoes density gradient centrifugation to separate the mononuclear cell fraction containing the stem cells from red blood cells and granulocytes. If additional processing is ordered, advanced immunomagnetic cell separation is performed to isolate specific cell populations, such as CD34+ hematopoietic stem cells. The final cellular product is evaluated for total nucleated cell count, viability, and sterility before being prepared for immediate clinical use or cryopreserved in liquid nitrogen for future therapeutic applications.

When is a Stem Cell Procedure Performed?

Hematological Malignancies and Lymphoproliferative Disorders

Physicians frequently request stem cell processing and preparation for patients diagnosed with hematological malignancies, including leukemia (acute myeloid leukemia, acute lymphoblastic leukemia), lymphoma (Hodgkin and non-Hodgkin lymphoma), and multiple myeloma. In these conditions, high-dose chemotherapy or radiation is utilized to destroy malignant cells, which unfortunately also destroys the patient’s healthy bone marrow. A stem cell procedure is performed to harvest and process healthy stem cells prior to therapy, which are then reinfused to rescue and reconstitute the patient’s hematopoietic system, allowing them to produce healthy blood cells once again.

Bone Marrow Failure Syndromes and Aplastic Anemia

In cases of severe aplastic anemia, myelodysplastic syndromes (MDS), or other bone marrow failure disorders, the body’s natural ability to produce red blood cells, white blood cells, and platelets is severely compromised. A stem cell procedure utilizing donor stem cells (allogeneic transplantation) is often the definitive treatment of choice. The laboratory processing at Chughtai Lab ensures that the donor cells are highly viable, properly characterized, and free of pathogens, which is critical to minimizing the risk of graft failure or graft-versus-host disease (GVHD) in these vulnerable patients.

Orthopedic and Musculoskeletal Regenerative Medicine

Regenerative medicine specialists utilize mesenchymal stem cells (MSCs) derived from bone marrow or adipose tissue to treat severe degenerative joint diseases, non-union bone fractures, and tendon or ligament injuries. When conservative treatments fail, physicians may opt for a stem cell procedure to harvest, concentrate, and process these regenerative cells. The processed stem cells are then injected directly into the affected joint or tissue to promote accelerated healing, reduce chronic inflammation, and stimulate tissue regeneration.

Autoimmune and Inflammatory Diseases

Advanced clinical protocols increasingly utilize autologous hematopoietic stem cell transplantation (AHSCT) for severe, treatment-resistant autoimmune diseases, such as multiple sclerosis (MS), systemic sclerosis, and Crohn’s disease. The therapeutic goal is to “reset” the patient’s malfunctioning immune system. The stem cell procedure involves harvesting the patient’s stem cells, purifying them in the laboratory to remove auto-reactive lymphocytes, administering immunoablative therapy to the patient, and then reinfusing the processed stem cells to rebuild a healthy, non-aggressive immune system.

Congenital Metabolic and Immunodeficiency Disorders

Pediatric and genetic specialists recommend stem cell procedures for children born with severe combined immunodeficiency (SCID), Hurler syndrome, osteopetrosis, or hemoglobinopathies like Thalassemia Major and Sickle Cell Disease. For these genetic disorders, a successful allogeneic stem cell transplant can provide a lifelong cure. Chughtai Lab’s meticulous cellular processing, viability testing, and cell count verification are vital to ensuring that the pediatric recipient receives an optimal therapeutic dose of functional stem cells capable of correcting the underlying genetic deficiency.

What Does a Stem Cell Procedure Detect or Evaluate?

During the laboratory processing phase of a stem cell procedure, Chughtai Lab evaluates a comprehensive array of cellular, microbiological, and physical parameters to ensure the safety, purity, and potency of the cellular product. The laboratory analysis evaluates the following critical components:

• Total Nucleated Cell (TNC) Count: Measures the absolute number of nucleated cells in the harvested sample, which is a primary indicator of graft adequacy.
• CD34+ Absolute Cell Count: Quantifies the specific marker for hematopoietic stem and progenitor cells, essential for predicting successful engraftment.
• CD34+ Cell Percentage: Determines the proportion of stem cells relative to the total mononuclear cell population.
• Cell Viability (Trypan Blue/Flow Cytometry): Assesses the percentage of living cells within the sample, ensuring that only viable cells are prepared for infusion.
• Aerobic Bacterial Culture: Screens the processed sample for potential aerobic bacterial contamination to prevent systemic infection in the recipient.
• Anaerobic Bacterial Culture: Detects anaerobic bacterial pathogens that could compromise the safety of the cellular product.
• Fungal Culture: Ensures the sample is free from fungal contaminants, which pose a severe threat to immunocompromised patients.
• Mycoplasma Contamination Testing: Utilizes molecular methods to rule out sub-microscopic mycoplasma contamination in cell cultures.
• Endotoxin Levels: Measures bacterial endotoxins to guarantee the pyrogen-free status of the final cellular preparation.
• Hematocrit (HCT) Levels: Evaluates the red blood cell content of the harvest, guiding the necessity for red cell depletion.
• Mononuclear Cell (MNC) Yield: Measures the concentration of lymphocytes and monocytes, which contain the therapeutic stem cell fraction.
• Granulocyte Contamination: Assesses the level of remaining granulocytes, which can release inflammatory mediators during storage.
• Platelet Contamination: Evaluates platelet levels, as excessive platelets can cause cellular clumping and reduce stem cell viability.
• HLA Typing Compatibility: Verifies the human leukocyte antigen match between donor and recipient in allogeneic procedures.
• Post-Thaw Viability: Measures the survival rate of stem cells after cryopreservation and subsequent thawing.
• Cell Recovery Rate: Calculates the percentage of stem cells successfully recovered after processing compared to the raw harvest.
• Red Blood Cell Depletion Efficiency: Measures the success of removing incompatible or excess red blood cells from the sample.
• Volume of Final Concentrate: Ensures the final volume is optimized for safe clinical infusion or cryopreservation.
• Cryoprotectant Concentration: Monitors the levels of dimethyl sulfoxide (DMSO) or other cryoprotectants to prevent cellular toxicity.
• pH of the Cellular Product: Verifies that the physiological pH is maintained throughout processing to preserve cell function.
• Sterility of Processing Reagents: Confirms that all media, enzymes, and solutions used during processing are completely sterile.
• Integrity of Cryopreservation Bags: Inspects the physical storage containers for leaks or micro-tears prior to long-term storage.
• Temperature Log Consistency: Reviews continuous temperature monitoring data during transport and processing to ensure cold chain integrity.
• Total Processing Duration: Documents the exact time elapsed from collection to final processing to minimize ischemic cell damage.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is widely recognized for its efficient, highly accurate, and technologically advanced reporting systems. For specialized procedures like stem cell processing, turnaround times are carefully managed to align with clinical transplantation schedules. Initial cell counts, viability assessments, and flow cytometry results (such as CD34+ quantification) are typically completed within 24 to 48 hours of sample receipt, as these parameters are critical for immediate clinical decision-making. Final sterility cultures (bacterial and fungal) require extended incubation periods and are reported progressively, with final confirmation typically completed within 7 to 14 days to ensure absolute safety.

Patients and referring physicians can access reports seamlessly through Chughtai Lab’s advanced digital infrastructure. Reports are made available online via the official Chughtai Lab website portal and the dedicated Chughtai Active Mobile App. Additionally, automated SMS notifications are sent to patients as soon as their verified reports are ready for download. For critical cellular therapies, Chughtai Lab’s pathology consultants communicate directly with the referring clinical team to provide immediate verbal updates of cell counts and viability metrics, ensuring seamless coordination of patient care.

Stem Cell Procedure Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CD34+ Cell Viability	≥ 70% viable cells post-thaw / processing	< 70% viability, indicating cellular damage or poor preservation
Total Nucleated Cell (TNC) Count	≥ 2.0 x 10^8 cells/kg of recipient weight	Sub-therapeutic cell count, increasing risk of graft failure
CD34+ Absolute Count	≥ 2.0 x 10^6 CD34+ cells/kg of recipient weight	Inadequate stem cell dose, requiring additional harvesting
Microbial Sterility Culture	No growth of bacteria or fungi after 14 days	Growth of pathogens (e.g., Staphylococcus, Candida), indicating contamination
Endotoxin Concentration	< 0.5 EU/mL (Endotoxin Units per milliliter)	Elevated endotoxin levels, indicating bacterial pyrogen contamination
Mycoplasma PCR	Negative / Not Detected	Positive detection, requiring sample rejection or specialized treatment
Red Blood Cell (RBC) Depletion	> 90% depletion of original RBC volume	Incomplete depletion, increasing risk of hemolytic transfusion reactions
pH of Cellular Medium	7.20 to 7.45 (Physiological range)	Acidic or alkaline pH, indicating cellular stress or metabolic decline

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Stem Cell Procedure?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified cellular pathologists, hematologists, and laboratory technologists specializing in advanced cellular therapies.
• Patient-Focused Care: Every stem cell processing protocol is tailored to the specific clinical requirements of the patient, ensuring personalized attention and care.
• Quality Diagnostic Services: Chughtai Lab adheres to rigorous international quality control standards, ensuring maximum accuracy in cell counting and viability testing.
• Professional Reporting: Detailed, comprehensive, and easy-to-understand reports are provided promptly to facilitate timely clinical interventions.
• Modern Diagnostic Approach: Utilizing state-of-the-art flow cytometry, automated cell counters, and sterile cleanroom technology for superior cellular processing.
• Comfortable Environment: Convenient sample collection centers and professional staff ensure a stress-free experience for patients and donors.
• Convenient Location: With a vast network of laboratories and collection centers across Pakistan, Chughtai Lab is easily accessible to patients nationwide.
• Commitment to Accurate Diagnosis: Dedicated to providing reliable, evidence-based diagnostic and processing services that clinicians trust for critical patient care.